AFMD Jul 2024 1.000 call
| Previous Close | 0.1000 |
| Open | 0.1500 |
| Bid | 0.0000 |
| Ask | 0.2500 |
| Strike | 1.00 |
| Expire Date | 2024-07-19 |
| Day's Range | 0.1500 - 0.1500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 362 |
GlobeNewswireAffimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress
Treatment with AFM28 innate cell engager (ICE®), designed to target CD123-positive cancer cells in patients with acute myeloid leukemia (AML), led to dose-dependent tumor growth control in a validated in vivo mouse modelAFM28 led to an effective reduction of CD123-expressing AML patient-derived leukemic blasts and stem cells in a newly engineered ex vivo bone marrow niche model MANNHEIM, Germany, May 14, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology compa
ZacksImmatics (IMTX) Reports Q1 Loss, Tops Revenue Estimates
Immatics (IMTX) delivered earnings and revenue surprises of 94.59% and 85.05%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ZacksWall Street Analysts Believe Affimed N.V. (AFMD) Could Rally 146.73%: Here's is How to Trade
The consensus price target hints at a 146.7% upside potential for Affimed N.V. (AFMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
